Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma.

Van Tine BA, Agulnik M, Olson RD, Walsh GM, Klausner A, Frank NE, Talley TT, Milhem MM.

Cancer Med. 2019 Jun;8(6):2994-3003. doi: 10.1002/cam4.2136. Epub 2019 Apr 23.

2.

Molecular determinants of α-conotoxin potency for inhibition of human and rat α6β4 nicotinic acetylcholine receptors.

Hone AJ, Talley TT, Bobango J, Huidobro Melo C, Hararah F, Gajewiak J, Christensen S, Harvey PJ, Craik DJ, McIntosh JM.

J Biol Chem. 2018 Nov 16;293(46):17838-17852. doi: 10.1074/jbc.RA118.005649. Epub 2018 Sep 24.

3.
4.

Synthesis of selective agonists for the α7 nicotinic acetylcholine receptor with in situ click-chemistry on acetylcholine-binding protein templates.

Yamauchi JG, Gomez K, Grimster N, Dufouil M, Nemecz A, Fotsing JR, Ho KY, Talley TT, Sharpless KB, Fokin VV, Taylor P.

Mol Pharmacol. 2012 Oct;82(4):687-99. Epub 2012 Jul 11.

5.

The effect of crebanine on memory and cognition impairment via the alpha-7 nicotinic acetylcholine receptor.

Rojsanga P, Boonyarat C, Utsintong M, Nemecz Á, Yamauchi JG, Talley TT, Olson AJ, Matsumoto K, Vajragupta O.

Life Sci. 2012 Aug 21;91(3-4):107-14. doi: 10.1016/j.lfs.2012.06.017. Epub 2012 Jun 28.

PMID:
22749860
6.

Generation of candidate ligands for nicotinic acetylcholine receptors via in situ click chemistry with a soluble acetylcholine binding protein template.

Grimster NP, Stump B, Fotsing JR, Weide T, Talley TT, Yamauchi JG, Nemecz Á, Kim C, Ho KY, Sharpless KB, Taylor P, Fokin VV.

J Am Chem Soc. 2012 Apr 18;134(15):6732-40. doi: 10.1021/ja3001858. Epub 2012 Apr 6.

7.

Docking studies of benzylidene anabaseine interactions with α7 nicotinic acetylcholine receptor (nAChR) and acetylcholine binding proteins (AChBPs): application to the design of related α7 selective ligands.

Kombo DC, Mazurov A, Tallapragada K, Hammond PS, Chewning J, Hauser TA, Vasquez-Valdivieso M, Yohannes D, Talley TT, Taylor P, Caldwell WS.

Eur J Med Chem. 2011 Nov;46(11):5625-35. doi: 10.1016/j.ejmech.2011.09.033. Epub 2011 Sep 29.

8.

Virtual screening against acetylcholine binding protein.

Utsintong M, Rojsanga P, Ho KY, Talley TT, Olson AJ, Matsumoto K, Vajragupta O.

J Biomol Screen. 2012 Feb;17(2):204-15. doi: 10.1177/1087057111421667. Epub 2011 Sep 28.

9.

Characterizing ligand-gated ion channel receptors with genetically encoded Ca2++ sensors.

Yamauchi JG, Nemecz Á, Nguyen QT, Muller A, Schroeder LF, Talley TT, Lindstrom J, Kleinfeld D, Taylor P.

PLoS One. 2011 Jan 28;6(1):e16519. doi: 10.1371/journal.pone.0016519.

10.

Structural determinants in phycotoxins and AChBP conferring high affinity binding and nicotinic AChR antagonism.

Bourne Y, Radic Z, Aráoz R, Talley TT, Benoit E, Servent D, Taylor P, Molgó J, Marchot P.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):6076-81. doi: 10.1073/pnas.0912372107. Epub 2010 Mar 11.

11.

Virtual screening against alpha-cobratoxin.

Utsintong M, Talley TT, Taylor PW, Olson AJ, Vajragupta O.

J Biomol Screen. 2009 Oct;14(9):1109-18. doi: 10.1177/1087057109344617. Epub 2009 Sep 4.

12.

Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal alpha7 nicotinic acetylcholine receptor.

Hibbs RE, Sulzenbacher G, Shi J, Talley TT, Conrod S, Kem WR, Taylor P, Marchot P, Bourne Y.

EMBO J. 2009 Oct 7;28(19):3040-51. doi: 10.1038/emboj.2009.227. Epub 2009 Aug 20.

13.

Natural variation within the neuronal nicotinic acetylcholine receptor cluster on human chromosome 15q24: influence on heritable autonomic traits in twin pairs.

Rana BK, Wessel J, Mahboubi V, Rao F, Haeller J, Gayen JR, Eskin E, Valle AM, Das M, Mahata SK, Taupenot L, Stridsberg M, Talley TT, Ziegler MG, Smith DW, Schork NJ, O'Connor DT, Taylor P.

J Pharmacol Exp Ther. 2009 Nov;331(2):419-28. doi: 10.1124/jpet.109.157271. Epub 2009 Aug 11.

14.

Nicotinic agonist binding site mapped by methionine- and tyrosine-scanning coupled with azidochloropyridinyl photoaffinity labeling.

Tomizawa M, Talley TT, Park JF, Maltby D, Medzihradszky KF, Durkin KA, Cornejo-Bravo JM, Burlingame AL, Casida JE, Taylor P.

J Med Chem. 2009 Jun 25;52(12):3735-41. doi: 10.1021/jm900153c.

15.

A virtual screening study of the acetylcholine binding protein using a relaxed-complex approach.

Babakhani A, Talley TT, Taylor P, McCammon JA.

Comput Biol Chem. 2009 Apr;33(2):160-70. doi: 10.1016/j.compbiolchem.2008.12.002. Epub 2009 Jan 8.

16.

Atomic interactions of neonicotinoid agonists with AChBP: molecular recognition of the distinctive electronegative pharmacophore.

Talley TT, Harel M, Hibbs RE, Radic Z, Tomizawa M, Casida JE, Taylor P.

Proc Natl Acad Sci U S A. 2008 May 27;105(21):7606-11. doi: 10.1073/pnas.0802197105. Epub 2008 May 13.

17.

Atypical nicotinic agonist bound conformations conferring subtype selectivity.

Tomizawa M, Maltby D, Talley TT, Durkin KA, Medzihradszky KF, Burlingame AL, Taylor P, Casida JE.

Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1728-32. doi: 10.1073/pnas.0711724105. Epub 2008 Jan 29.

18.

Structure-guided drug design: conferring selectivity among neuronal nicotinic receptor and acetylcholine-binding protein subtypes.

Taylor P, Talley TT, Radic' Z, Hansen SB, Hibbs RE, Shi J.

Biochem Pharmacol. 2007 Oct 15;74(8):1164-71. Epub 2007 Aug 3. Review.

19.

Defining nicotinic agonist binding surfaces through photoaffinity labeling.

Tomizawa M, Maltby D, Medzihradszky KF, Zhang N, Durkin KA, Presley J, Talley TT, Taylor P, Burlingame AL, Casida JE.

Biochemistry. 2007 Jul 31;46(30):8798-806. Epub 2007 Jul 6.

20.

Mapping the elusive neonicotinoid binding site.

Tomizawa M, Talley TT, Maltby D, Durkin KA, Medzihradszky KF, Burlingame AL, Taylor P, Casida JE.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):9075-80. Epub 2007 May 7.

21.

Protein folding determinants: structural features determining alternative disulfide pairing in alpha- and chi/lambda-conotoxins.

Kang TS, Radić Z, Talley TT, Jois SD, Taylor P, Kini RM.

Biochemistry. 2007 Mar 20;46(11):3338-55. Epub 2007 Feb 22.

22.

Structural comparison of three crystalline complexes of a peptidic toxin with a synaptic acetylcholine recognition protein.

Bourne Y, Hansen SB, Sulzenbacher G, Talley TT, Huxford T, Taylor P, Marchot P.

J Mol Neurosci. 2006;30(1-2):103-4.

23.
24.

Alpha-conotoxin OmIA is a potent ligand for the acetylcholine-binding protein as well as alpha3beta2 and alpha7 nicotinic acetylcholine receptors.

Talley TT, Olivera BM, Han KH, Christensen SB, Dowell C, Tsigelny I, Ho KY, Taylor P, McIntosh JM.

J Biol Chem. 2006 Aug 25;281(34):24678-86. Epub 2006 Jun 27.

25.

Crystal structure of a Cbtx-AChBP complex reveals essential interactions between snake alpha-neurotoxins and nicotinic receptors.

Bourne Y, Talley TT, Hansen SB, Taylor P, Marchot P.

EMBO J. 2005 Apr 20;24(8):1512-22. Epub 2005 Mar 24. Erratum in: EMBO J. 2006 Jan 11;25(1):266.

26.
27.

Structural and ligand recognition characteristics of an acetylcholine-binding protein from Aplysia californica.

Hansen SB, Talley TT, Radic Z, Taylor P.

J Biol Chem. 2004 Jun 4;279(23):24197-202. Epub 2004 Apr 6.

28.

Contemporary paradigms for cholinergic ligand design guided by biological structure.

Taylor P, Hansen SB, Talley TT, Hibbs RE, Radić Z.

Bioorg Med Chem Lett. 2004 Apr 19;14(8):1875-7. Review.

29.

Curariform antagonists bind in different orientations to acetylcholine-binding protein.

Gao F, Bern N, Little A, Wang HL, Hansen SB, Talley TT, Taylor P, Sine SM.

J Biol Chem. 2003 Jun 20;278(25):23020-6. Epub 2003 Apr 7.

30.

Tryptophan fluorescence reveals conformational changes in the acetylcholine binding protein.

Hansen SB, Radic' Z, Talley TT, Molles BE, Deerinck T, Tsigelny I, Taylor P.

J Biol Chem. 2002 Nov 1;277(44):41299-302. Epub 2002 Sep 13.

31.

Identification of butyrylcholinesterase adducts after inhibition with isomalathion using mass spectrometry: difference in mechanism between (1R)- and (1S)-stereoisomers.

Doorn JA, Schall M, Gage DA, Talley TT, Thompson CM, Richardson RJ.

Toxicol Appl Pharmacol. 2001 Oct 15;176(2):73-80.

PMID:
11601883
33.

Inhibition of acetylcholinesterase by (1S,3S)-isomalathion proceeds with loss of thiomethyl: kinetic and mass spectral evidence for an unexpected primary leaving group.

Doorn JA, Gage DA, Schall M, Talley TT, Thompson CM, Richardson RJ.

Chem Res Toxicol. 2000 Dec;13(12):1313-20.

PMID:
11123973
34.

Kinetic evidence for different mechanisms of acetylcholinesterase inhibition by (1R)- and (1S)-stereoisomers of isomalathion.

Jianmongkol S, Marable BR, Berkman CE, Talley TT, Thompson CM, Richardson RJ.

Toxicol Appl Pharmacol. 1999 Feb 15;155(1):43-53.

PMID:
10036217
35.

XAD-4 resin hemoperfusion for digitoxic patients with renal failure.

Hoy WE, Gibson TP, Rivero AJ, Jain VK, Talley TT, Bayer RM, Montondo DF, Freeman RB.

Kidney Int. 1983 Jan;23(1):79-82. No abstract available.

Supplemental Content

Loading ...
Support Center